Cargando…

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V(H) regions are functional as single domains, forming the smallest active antibody fragment. These V(H) regions are ideal building blocks for a variety of antibody-based biologics because they tolerate fusion to other...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Starlynn C., Ma, Biao, Trinklein, Nathan D., Schellenberger, Ute, Osborn, Michael J., Ouisse, Laure-Hélène, Boudreau, Andrew, Davison, Laura M., Harris, Katherine E., Ugamraj, Harshad S., Balasubramani, Aarti, Dang, Kevin H., Jorgensen, Brett, Ogana, Heather Anne N., Pham, Duy T., Pratap, Payal P., Sankaran, Preethi, Anegon, Ignacio, van Schooten, Wim C., Brüggemann, Marianne, Buelow, Roland, Force Aldred, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330309/
https://www.ncbi.nlm.nih.gov/pubmed/30666250
http://dx.doi.org/10.3389/fimmu.2018.03037
_version_ 1783386943619334144
author Clarke, Starlynn C.
Ma, Biao
Trinklein, Nathan D.
Schellenberger, Ute
Osborn, Michael J.
Ouisse, Laure-Hélène
Boudreau, Andrew
Davison, Laura M.
Harris, Katherine E.
Ugamraj, Harshad S.
Balasubramani, Aarti
Dang, Kevin H.
Jorgensen, Brett
Ogana, Heather Anne N.
Pham, Duy T.
Pratap, Payal P.
Sankaran, Preethi
Anegon, Ignacio
van Schooten, Wim C.
Brüggemann, Marianne
Buelow, Roland
Force Aldred, Shelley
author_facet Clarke, Starlynn C.
Ma, Biao
Trinklein, Nathan D.
Schellenberger, Ute
Osborn, Michael J.
Ouisse, Laure-Hélène
Boudreau, Andrew
Davison, Laura M.
Harris, Katherine E.
Ugamraj, Harshad S.
Balasubramani, Aarti
Dang, Kevin H.
Jorgensen, Brett
Ogana, Heather Anne N.
Pham, Duy T.
Pratap, Payal P.
Sankaran, Preethi
Anegon, Ignacio
van Schooten, Wim C.
Brüggemann, Marianne
Buelow, Roland
Force Aldred, Shelley
author_sort Clarke, Starlynn C.
collection PubMed
description Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V(H) regions are functional as single domains, forming the smallest active antibody fragment. These V(H) regions are ideal building blocks for a variety of antibody-based biologics because they tolerate fusion to other molecules and may also be attached in series to construct multispecific antibodies without the need for protein engineering to ensure proper heavy and light chain pairing. Production of human HCAbs has been impeded by the fact that natural human V(H) regions require light chain association and display poor biophysical characteristics when expressed in the absence of light chains. Here, we present an innovative platform for the rapid development of diverse sets of human HCAbs that have been selected in vivo. Our unique approach combines antibody repertoire analysis with immunization of transgenic rats, called UniRats, that produce chimeric HCAbs with fully human V(H) domains in response to an antigen challenge. UniRats express HCAbs from large transgenic loci representing the entire productive human heavy chain V(D)J repertoire, mount robust immune responses to a wide array of antigens, exhibit diverse V gene usage and generate large panels of stable, high affinity, antigen-specific molecules.
format Online
Article
Text
id pubmed-6330309
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63303092019-01-21 Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies Clarke, Starlynn C. Ma, Biao Trinklein, Nathan D. Schellenberger, Ute Osborn, Michael J. Ouisse, Laure-Hélène Boudreau, Andrew Davison, Laura M. Harris, Katherine E. Ugamraj, Harshad S. Balasubramani, Aarti Dang, Kevin H. Jorgensen, Brett Ogana, Heather Anne N. Pham, Duy T. Pratap, Payal P. Sankaran, Preethi Anegon, Ignacio van Schooten, Wim C. Brüggemann, Marianne Buelow, Roland Force Aldred, Shelley Front Immunol Immunology Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V(H) regions are functional as single domains, forming the smallest active antibody fragment. These V(H) regions are ideal building blocks for a variety of antibody-based biologics because they tolerate fusion to other molecules and may also be attached in series to construct multispecific antibodies without the need for protein engineering to ensure proper heavy and light chain pairing. Production of human HCAbs has been impeded by the fact that natural human V(H) regions require light chain association and display poor biophysical characteristics when expressed in the absence of light chains. Here, we present an innovative platform for the rapid development of diverse sets of human HCAbs that have been selected in vivo. Our unique approach combines antibody repertoire analysis with immunization of transgenic rats, called UniRats, that produce chimeric HCAbs with fully human V(H) domains in response to an antigen challenge. UniRats express HCAbs from large transgenic loci representing the entire productive human heavy chain V(D)J repertoire, mount robust immune responses to a wide array of antigens, exhibit diverse V gene usage and generate large panels of stable, high affinity, antigen-specific molecules. Frontiers Media S.A. 2019-01-07 /pmc/articles/PMC6330309/ /pubmed/30666250 http://dx.doi.org/10.3389/fimmu.2018.03037 Text en Copyright © 2019 Clarke, Ma, Trinklein, Schellenberger, Osborn, Ouisse, Boudreau, Davison, Harris, Ugamraj, Balasubramani, Dang, Jorgensen, Ogana, Pham, Pratap, Sankaran, Anegon, van Schooten, Brüggemann, Buelow and Force Aldred. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Clarke, Starlynn C.
Ma, Biao
Trinklein, Nathan D.
Schellenberger, Ute
Osborn, Michael J.
Ouisse, Laure-Hélène
Boudreau, Andrew
Davison, Laura M.
Harris, Katherine E.
Ugamraj, Harshad S.
Balasubramani, Aarti
Dang, Kevin H.
Jorgensen, Brett
Ogana, Heather Anne N.
Pham, Duy T.
Pratap, Payal P.
Sankaran, Preethi
Anegon, Ignacio
van Schooten, Wim C.
Brüggemann, Marianne
Buelow, Roland
Force Aldred, Shelley
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title_full Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title_fullStr Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title_full_unstemmed Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title_short Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
title_sort multispecific antibody development platform based on human heavy chain antibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330309/
https://www.ncbi.nlm.nih.gov/pubmed/30666250
http://dx.doi.org/10.3389/fimmu.2018.03037
work_keys_str_mv AT clarkestarlynnc multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT mabiao multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT trinkleinnathand multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT schellenbergerute multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT osbornmichaelj multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT ouisselaurehelene multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT boudreauandrew multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT davisonlauram multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT harriskatherinee multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT ugamrajharshads multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT balasubramaniaarti multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT dangkevinh multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT jorgensenbrett multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT oganaheatherannen multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT phamduyt multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT pratappayalp multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT sankaranpreethi multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT anegonignacio multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT vanschootenwimc multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT bruggemannmarianne multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT buelowroland multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies
AT forcealdredshelley multispecificantibodydevelopmentplatformbasedonhumanheavychainantibodies